Study drug lurbinectedin with weekly paclitaxel and bevacizumab
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to sign consent.
- You have ovarian, fallopian tube, or peritoneal cancer proven by biopsy, and it must be platinum-resistant or platinum-refractory.
- You should be able to come for scheduled visits and take the study treatment for the planned time.
- Your blood counts and organ function must meet lab limits (enough red blood cells, white blood cells, platelets, and kidney/liver function).
- Your heart and infections must be stable enough for treatment, and you must not have certain serious health problems or major bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.